Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II

详细信息    查看全文

• 作者：Menno V. Huisman ; MD^a ; Kenneth J. Rothman ; DrPH^b ; Miney Paquette ; MSc^c ; Christine Teutsch ; MD^d ; Hans Christoph Diener ; MD^e ; Sergio J. Dubner ; MD^f ; Jonathan L. Halperin ; MD^g ; Changsheng Ma ; MD^h ; Kristina Zint ; MD^d ; Amelie Elsaesser ; MD^d ; Dorothee B. Bartels ; MD^d ; Gregory Y.H. Lip ; MDⁱ ; ^{g.y.h.lip@bham.ac.uk" class="auth_mail" title="E-mail the corresponding author} ; on behalf of the GLORIA-AF Investigators
• 关键词：Anticoagulation ; Atrial fibrillation ; Registry ; Stroke
• 刊名：The American Journal of Medicine
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：128
• 期：12
• 页码：1306-1313.e1
• 全文大小：1280 K

文摘

The Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) was designed to provide prospectively collected information on patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke, with the aim of addressing treatment patterns and questions of effectiveness and safety.

Methods and Results

In this predefined analysis from GLORIA-AF, the baseline characteristics and initial antithrombotic management of the first 10,000 patients in Phase II of this large Registry Program are presented. Overall, 32.3% of patients received vitamin K antagonists (VKAs) and 47.7% received non-VKA oral anticoagulants (NOACs), while 12.3% received antiplatelet treatment and 7.6% did not receive any antithrombotic treatment. Among patients with CHA₂DS₂-VASc score ≥2, 6.7% received no antithrombotic treatment and 10.0% received aspirin. In Europe, treatment with dabigatran was as common as treatment with VKAs (38.8% and 37.8%, respectively). More than half of the patients were treated with NOACs (52.4%), while antiplatelet treatment was given to 5.7%, and 4.1% did not receive any antithrombotic treatment. In North America, treatment with dabigatran (25.0%) was as common as with VKAs (26.1%), but overall NOAC use was more common (52.1%) than with VKAs (26.1%); however, 14.1% received antiplatelet treatment, while 7.6% received no antithrombotic treatment. In Asia, treatment with VKAs (31.9%) was more prevalent than NOACs (25.5%), but antiplatelet treatment was given to 25.8%, and 16.9% did not receive any antithrombotic treatment. In Asia, only 60.7% of patients with high stroke risk received oral anticoagulants (OACs). Paroxysmal atrial fibrillation and minimally symptomatic (or asymptomatic) patients were often undertreated with OACs.

Conclusion

In this analysis, OAC use was high in Europe and North America, with overall NOAC use higher than VKA use. A considerable percentage of high-risk patients in North America still received antiplatelet treatment or were untreated, while Asian patients had a high proportion of aspirin use and nontreatment.